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Most blinded, late stage, randomized clinical trials package study drug, active or placebo, into drug kits
for distribution to investigational sites. Drug kits enable investigators to administer study drug to sub-
jects in a blinded manner without the assistance of an unblinded pharmacist. Supply methods determine
when and how many kits to send to sites. If not properly designed, these methods can partially unblind
investigators, i.e., investigators can conclude that two subjects are (1) on the same treatment arm with
certainty or (2) on different treatment arms with certainty. Partial unblinding can bias the way in-
vestigators provide patient care, report adverse events and assess efﬁcacy endpoints, and can lead to full
unblinding when the other subject is unblinded. In this paper, we describe several examples of partial
unblinding in the supply methods commonly used by many Randomization and Trial Supply Manage-
ment (RTSM) systems, propose a new criterion for evaluating the blinding properties of supply methods,
and prove that two alternative supply methods do not permit full or partial unblinding, even after the
investigator is unblinded up to a certain number of other subjects.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ensuring sufﬁcient study drug supplies at sites is a requirement
of every clinical trial. The primary difﬁculty lies in the requirement
of maintaining a standing inventory of drug kits at sites to dose
subjects when subjects are randomized. This requirement stems
from the common practice of dosing subjects on the same day or
within 1e2 days of randomization in order to prevent early with-
drawals as well as provide subject convenience. Under these cir-
cumstances, there is not sufﬁcient time to ship a kit to the site on an
as-needed basis. Instead a standing inventory of kits must be
maintained at sites. The size of this inventory must be large enough
to accommodate subject randomizations that are not known ahead
of time but not too large to cause a signiﬁcant waste.
For blinded studies, ensuring the blind is also of crucial impor-
tance. There are two kinds of unblinding: full unblinding and par-
tial unblinding [1]. Full unblinding occurs when an investigator
learns the kit type of a particular kit. Partial unblinding occurs
when an investigator can conclude with certainty that two kits are
of the same kit type or conclude with certainty that two kits are ofp 44-2B South San Francisco,
Inc. This is an open access article udifferent kit types. Both full and partial unblinding should be
avoided.
To prevent unblinding by investigators, randomness should be
incorporated in each step of the “life-cycle” of a drug kit, including
packaging and labeling, supplying to sites and assigning to subjects.
Drug kit labeling methods and their blinding properties have been
discussed extensively in the literature [1e3]. In regard to assigning
kits to subjects, it is known that deterministic methods such as
assigning kits from the earliest shipments ﬁrst (i.e., ﬁrst-in-ﬁrst-out
[FIFO]) can partially unblind investigators [4]. This paper describes
several methods for supplying kits and compares their blinding
properties.
This paper is organized as follows. Section 2 describes two
supply strategies to illustrate the trade-off between ensuring the
blind and kit efﬁciency (i.e., total number of kits required for the
trial; supply methods that require fewer kits for the trial are more
efﬁcient). Sections 3 and 4 describe the widely used Trigger-and-
Resupply (TR) and Predictive Resupply (PR) methods [5,6] and
their poor blinding properties. Because Randomization and Trial
Supply Management (RTSM) system implementations are pro-
prietary, our descriptions of these methods may be somewhat
different from actual vendor implementations. Section 5 proposes a
new criterion called Strong Blinding for evaluating the blindingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Blinded Group Ordering (BGO) [7] and Extended Blinded Group
Ordering (EBGO) methods and their superior blinding properties.
The BGO method was originally devised to minimize drug kit
wastage at low enrolling sites [7] without endangering the blind
but does not appear to be widely used yet. In the Addendum, the
BGO method for two-arm trials is proved to be strongly blinding.
For brevity, our descriptions of supply methods are limited to
two-arm placebo-controlled trials in which subjects are random-
ized to one of the two arms in a 1:1 ratio and receive one kit per
visit. However the descriptions can be generalized tomore complex
trials such as: multi-arm studies, studies with unequal allocation,
etc.
2. Trade-off between blinding and efﬁciency
There is a trade-off between ensuring the blind and kit efﬁ-
ciency. To see this, consider the task of supplying kits in single
dispensation trials, i.e., trials in which a single drug kit contains a
subject's drug for the entire study. Antibiotic and vaccine trials are
often single dispensation trials. Two simple supply methods, Naïve
Replacement (NR) and Waste-One-Kit (WOK), illustrate the ex-
tremes of this trade-off.
 Naïve Replacement (poor blinding, high efﬁciency): After a kit at
the site is given to a subject, this method sends a replacement
kit to the site. Because the replacement kit is of the same kit type
as the kit that was used, the investigator is partially unblinded
when the replacement kit is used to dose a subject. That is, the
investigator can conclude that the subject who is dosed with the
replacement kit and the subject whowas dosed with the kit that
initiated the shipment of the replacement kit are on the same
treatment arm.
 Waste-One-Kit (excellent blinding, low efﬁciency): This method
protects the blind at the expense of wasting one kit per subject.
It sends kits to sites in pairs: one active and one placebo. After a
subject is randomized to receive either active or placebo kit, the
unused kit in the pair is deactivated and a new pair of kits is sent
to the site. Deactivating and not assigning the unused kit to a
future subject eliminates any information regarding the used
kit.
A good supply strategy will fall between these extremes and
ensure the blind while minimizing the number of kits that are
needed.
3. Trigger-and-resupply (TR) method
The TR method is implemented in many RTSM systems for
supplying kits to sites in single dispensation studies. Each study site
is assigned a trigger level and a resupply level for each kit type.When
the number of kits of a certain kit type falls to or below its trigger
level, a resupply shipment is sent to the site to bring the site's in-
ventories back to the resupply level. Usually all kit types are
brought up to their resupply levels, not just the kit type that has
triggered the resupply. Extensions of the method exist; for
example, a pre-speciﬁed number of random kits (randomly selected
kits) can be added to a shipment in order to blind the shipment.
The trigger level is a function of accrual rate and delivery time. It
is set sufﬁciently high so that newly randomized subjects can be
dosed even while the requested stock is in transit; hence, the
trigger level should be at least 1. The resupply level is set to match
the accrual rate; the level is set high enough to provide drug to new
subjects and to limit the frequency of resupplies but not so high to
avoid risk of medication expiring and inventory exceeding sitestorage capacity.
The TR method is vulnerable to partial unblinding, more so at
low enrolling sites. At low enrolling sites, subject randomizations
are infrequent and inventories are kept to a minimum. This pro-
vides investigators with two pieces of useful information. First,
investigators can associate resupplies with the subject randomi-
zations that have initiated the resupplies if the time between
subject arrivals is longer than the time needed for resupply ship-
ments to arrive at the sites. Second, because the inventories are
kept to a minimum, the choices for parameter values are limited:
usually the initial shipment will consist of 2 kits of each kit type, the
trigger levels will be 1, the resupply levels will be either 2 or 3, and
the number of random kits (if any) will be 1.
Here are some examples in which investigators can partially
unblind kits (and hence subjects) when these two pieces of useful
information are available. In the examples below, it is assumed that
the initial shipment consists of 4 kits; the investigators would
speculate correctly that it consists of 2 active and 2 placebo kits;
and the ﬁrst subject triggers a resupply.
1) When the ﬁrst resupply shipment consists of 2 kits, the inves-
tigator would speculate correctly that the resupply level is 2 and
that the ﬁrst resupply shipment contains one replacement kit (a
kit of the same type as the kit given to the ﬁrst subject) and one
random kit. Suppose the second subject receives a kit from the
ﬁrst resupply shipment. If another resupply is triggered, then
the investigator can conclude that the second subject has
received the replacement kit, both subjects are on the same
treatment arm, and the random kit is for the other treatment
arm. If the second subject doesn't trigger a resupply, then the
remaining kit in the ﬁrst resupply shipment must be of the same
type as the kit used to treat the ﬁrst subject.
2) When the ﬁrst resupply shipment consists of 3 kits, the inves-
tigator would speculate correctly that the resupply level is 3.
Because the site's inventory consists of 3 active and 3 placebo
kits after receiving the ﬁrst resupply shipment, the second
subject does not trigger a resupply. If the third subject triggers a
resupply, the investigator can conclude that the second and
third subjects are on the same treatment arm. If the third subject
does not trigger a resupply, the investigator can conclude that
the second and third subjects are on opposite arms.
Blinding shipments by adding two random kits instead of one,
an option offered by some RTSM systems, makes partial unblinding
less likely but does not eliminate it. Furthermore adding two
random kits increases site inventories and potentially the number
of kits needed for the trial.
If parameter values are revealed to the investigators and the
investigators can still associate resupplies with the subject ran-
domizations that have initiated the resupplies, then partial
unblinding can also occur at medium and high enrolling sites.
However the risk is lower because the difference between the
trigger and resupply levels has increased. If the difference between
the trigger and resupply levels is maintained, then the risk remains
the same.
4. Predictive Resupply (PR) method
The PR method is implemented in many RTSM systems to
supply kits to sites in multiple dispensation studies. In these
studies, drug kits are dispensed at more than one visit for a subject,
namely at randomization and at the subject's return visits. The PR
method extends the TR method with a prediction algorithm, which
is used to order kits for return visits. The number of kits required for
returning subjects can be predicted because subjects' visit
R. Yu, D.A. Coleman / Contemporary Clinical Trials Communications 1 (2015) 22e2724schedules are determined by the subjects' initial or previous visits.
Checks are made frequently, e.g. daily [6], to determine if
resupply shipments are needed. The check's ﬁrst step is to calculate
the number of kits needed for subjects' return visits over a deﬁned
time horizon called the check range. A resupply is initiated if a site's
inventory level falls to or below this number plus the TR trigger
level. This check is made for each kit type and a resupply is initiated
if the check is triggered for any kit type. The resupply shipment
contains kits needed for subjects' return visits over the prediction
window (typically a longer time horizon than the check range) as
well as kits to meet the TR resupply levels. Like the TR method,
random kits could be added to blind shipments; e.g., when the
resupply shipment contains kits for a single subject.
Thus the TR method maintains a buffer stock of kits for subjects'
ﬁrst visit (all kits in the initial shipment belong to the buffer stock)
and the prediction algorithm maintains a prediction stock of kits for
subjects' return visits. However, in order to reduce inventories at
sites and the number of kits needed for the trial, RTSM systems
typically do not differentiate between the buffer and prediction
stocks when dispensing kits to subjects. This practice and in-
adequacies inherited from the TR method can cause partial
unblinding in the PR method, for example:
1) Consider a site receiving an initial shipment of 4 kits (2 active
and 2 placebo kits). If a subject receives his/her ﬁrst and second
kit from the initial shipment, the investigator can conclude that
the remaining two kits in the initial shipment are of the opposite
type of the kits received by the ﬁrst subject.
2) Consider a site with two active subjects. Suppose the site peri-
odically receives shipments of two kits, one for each subject. If
one subject leaves the trial prior to using his/her kit and both
kits in the same shipment are used to dose the remaining sub-
ject, the investigator will learn that the two subjects are on the
same treatment arm.
3) Consider a site with two active subjects. Suppose the investi-
gator detects an increasing inventory of kits. The investigator
can conclude correctly that resupply shipments contain random
kits that can't be used to dose any of the subjects and that the
two subjects are on the same treatment arm.
4) If parameter values are revealed to the investigators, the PR
method could be susceptible to partial unblinding in the same
way as the TR method in single dispensation trials. Hence, like
the TR method, a site's parameters should be kept secret from
the site.5. Strong blinding, a criterion for evaluating strength of
blinding in a clinical trial
In this section, we introduce strong blinding as a measure of the
amount of information a supply method is able to shield from in-
vestigators in a blinded trial.
Deﬁnition 5.1: A supply method is said to be strongly blinding at
level n, n  1, if after being fully unblinded to any n  1 kits at the
site, an investigator is unable to:
a. Fully unblind a kit, or
b. Partially unblind two kits,
among the remaining kits (i.e., other than the n  1 kits that are
already fully unblinded at the site).
A supply method is strongly blinding at level 1 if it does not
allow full unblinding and partial unblinding, and is strongly
blinding at level 2 if it does not allow further full unblinding and
partial unblinding even after the investigator is fully unblinded toone kit. Higher levels of strong blinding impose more stringent
blinding than lower levels.
The NR, TR, and PR methods are not strongly blinding at any
level because partial unblinding can occur without the investigator
knowing the kit types of any kits. The WOK method is strongly
blinding at level inﬁnity.
The criterion strong blinding can in fact be applied to subject
randomization as well by replacing drug kits with subjects.
Deﬁnition 5.2: A randomization method is said to be strongly
blinding at level n, n  1, if after being fully unblinded to any n  1
subjects at the site, an investigator is unable to:
c. Fully unblind a subject, or
d. Partially unblind two subjects,
among the remaining subjects (i.e., other than the n  1 subjects
that are already fully unblinded at the site).
In studies where subjects are randomized in a 1:1 ratio to
receive one of the two treatment options, permuted block
randomization with a block size of 4 and Big Stick randomization
[8] with barrier a ¼ 2 are strongly blinding at level 2, and complete
randomization and Biased Coin randomization [9] are strongly
blinding at level inﬁnity. The level of strong blinding is of interest in
blinded clinical trials because it is not uncommon for an investi-
gator to be unblinded to a subject's treatment assignment for safety
reasons, or for an investigator to learn a subject's treatment
assignment from the subject's adverse event or efﬁcacy proﬁle.
6. Blinded Group Ordering (BGO)
The BGO method is a supply method for single dispensation
trials. The idea behind this method is to use a random kit to blind a
site's inventory instead of its shipments in order to minimize site
inventories and the total number of kits required for the trial. The
method has two parameters: the supply level k and the supply period
j. The supply level determines the inventory level at a site after
receiving the initial supply or a resupply shipment and the supply
period determines how often resupply shipments are sent to the
site.
For a two-arm trial with equal allocation, themethod starts with
an initial shipment of 2k þ 1 kits: k active kits, k placebo kits and 1
random kit. Resupply shipments, each consisting of j kits, are sent
after dosing every j subjects to bring the site's inventory back to
2k þ 1 kits. Resupply shipments are conﬁgured so that after a
resupply, the site again has either k active kits and k þ 1 placebo
kits, or k þ 1 active kits and k placebo kits. To avoid stockout of any
kit type at the site, we only consider 0 < j < k.
Depending on the inventory at the site, the conﬁguration of the
resupply shipmentmay be deterministic or stochastic. For example,
consider k ¼ 2 and j ¼ 1. Suppose the initial shipment consists of 2
active kits and 3 placebo kits. If the ﬁrst subject at the site is
assigned to the active arm, the resupply shipment has to be an
active kit; on the other hand, if the subject is assigned to the pla-
cebo arm, then the resupply shipment can be either an active kit or
a placebo kit, e.g. each with probability 1/2.
It should be noted that to adapt to changes in the site's accrual
rate during the trial, both supply level k and supply period j can be
adjusted. To increase the supply level from k to k þ 1, simply add 1
active and 1 placebo to the resupply shipment. To decrease k to
k  1, send a resupply shipment of j  1 kits so that after the
shipment arrives there are at least k 1 kits of each type at the site,
and then deactivate a kit so that the inventory at the site consists of
2k  1 kits with at least k  1 kits of each kit type. To adjust j, the
change can bemade after the site's inventory is replenished and has
2k þ 1 kits.
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number of kits needed at study startup. The modiﬁed strategy
sends 2k kits (k active and k placebo kits) instead of 2k þ 1 kits in
the initial shipment and sends j þ 1 kits, instead of j kits, in the ﬁrst
resupply shipment. After receiving the ﬁrst resupply shipment, the
site will have 2k þ 1 kits: k kits of one type and k þ 1 kits of the
other, and the usual strategy begins. Another advantage of this
modiﬁcation is that if no subjects are enrolled at a site, 2k kits are
wasted instead of 2k þ 1.
In the Addendumwe prove that for two-arm single dispensation
trials, the BGO method with j ¼ 1 is strongly blinding at level 3 and
the BGO method with j > 1 is strongly blinding at level j þ 1.
7. Extended Blinded Group Ordering (EBGO)
In this section we introduce the EBGO method, which extends
the BGO method to multiple dispensation studies. The EBGO uses
the BGO method to maintain a buffer stock of kits for subjects' ﬁrst
visit and the prediction algorithm (from the PR method) to main-
tain a prediction stock of kits for subjects' subsequent visits. Unlike
how the PR method is commonly implemented, the buffer stock
and the prediction stock are not mixed together. That is, kits in the
buffer stock are only used to dose newly randomized subjects and
kits in the prediction stock are only used to dose returning subjects.
Furthermore each kit in the prediction stock is pre-assigned to a
subject when it is shipped to the site; if the subject is discontinued
from treatment before the kit is used, then the kit is deactivated.
This distinction between the buffer stock and the prediction
stock and the pre-assignments of kits in the prediction stock to
subjects are made in the RTSM system, but should not be visible to
the sites until the kits are given to subjects for dosing.
The EBGOmethod is strongly blinding for subjects (as deﬁned in
Deﬁnition 5.2) at the same level as the underlying BGO method is
strongly blinding for kits (as deﬁned in Deﬁnition 5.1). For example
if the underlying BGOmethod is strongly blinding at level 3 for kits,
then the EBGO method is also strongly blinding at level 3, but for
subjects.
8. Discussion
Our investigation of supply strategies started when a statistician
asked us how to select TR parameters that would ensure the blind.
It was clear that adding more random kits to smaller shipments
increased the difﬁculty in detecting partial unblinding. However to
our surprise we were not able to ﬁnd parameter settings that we
could demonstrate did not permit partial unblinding. This led us to
investigate the blinding properties of alternative supply methods,
including the BGO and EBGO methods, and develop the strong
blinding criterion.
We show that for two-arm trials the BGO and EBGOmethods are
strongly blinding at a level of at least 3 even when the site
personnel and sponsor's clinical trial managers are aware of the
methods' parameters. Because the TR and PR methods permit
partial unblinding, we conclude that the blinding properties of the
BGO and EGBO methods are superior to those of the TR and PR
methods.
Both blinding and efﬁciency are important properties of a sup-
ply method. Efﬁciency includes keeping to a minimum the total
number of kits required for the study, the number or frequency of
resupply shipments, the number of initial kits to start the study and
the minimization of site inventories. Transitioning from the widely
used TR and PRmethods to the BGO and EBGOmethodswill require
that the efﬁciency of the BGO and EBGO methods be similar to or
better than the TR and PR methods. We believe that this may
indeed often be the case because the TR and PR methods addrandom kits to blind small shipments or shipments that may
contain kits for a single subject while the BGO and EBGO methods
add random kits to the initial shipments to blind sites' inventories.
Therefore when the number of small shipments or shipments that
may contain kits for a single subject exceeds the number of sites,
the efﬁciency of the BGO and EBGO methods should be as good as
or better than the TR and PR methods. However to thoroughly
compare efﬁciencies of different supply methods for a given study
design, simulations should be performed.
When a site has a small number of subjects who are still on
treatment and if all of them are on the same treatment arm, it
becomes difﬁcult to blind the investigator by blinding shipments
using random kits. This is due to the scenario as described in the
third example in Section 4, which could potentially occur. An
increasing inventory of kits at the site could lead the investigator to
conclude correctly that all the active subjects are on the same
treatment arm and the resupply shipments contain random kits
that can't be used to dose any of these subjects. Therefore instead of
blinding the shipments, blinding the site's inventorywill be a better
alternative to protect the blind, which is the approach taken by the
BGO and EBGO methods.
Another advantage of the BGO and EBGO methods is that
because there is no buildup of inventory at the site due to added
random kits, the size of inventory at the site is controlled. By
keeping more kits (kits that would otherwise be sent to the site as
random kits) at the depot rather than at the site, the BGO and EBGO
methods improve the ﬂexibility of supply chain.
As described earlier, the EBGO method pre-assigns kits in the
prediction stock to subjects in order to avoid unblinding. This pre-
assignment could result in drug kit wastage up to the amount of
supply need over the prediction window per subject, especially for
trials in which the treatment duration is not ﬁxed e for example,
subjects are often treated until disease progression in oncology
studies. The cost of pre-assignment, which fortunately does not
need to be paid at the beginning of a trial, has to beweighed against
the risk of unblinding.
We hope that the superior blinding properties of the BGO and
EBGO methods as demonstrated in this paper coupled with a
conﬁrmation of similar or improved efﬁciency, may convince
company sponsors and RTSM system providers to transition to the
BGO and EBGO methods to supply kits for suitable trials.
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Addendum
In this sectionwe show that the BGOmethod for two-arm single
dispensation trials (with k > j > 0) is strongly blinding at a level that
is at least 3.
Theorem A1
 The BGO method with j ¼ 1 (k > j) is strongly blinding at level 3
but not at level 4.
 The BGO method with j > 1 (k > j) is strongly blinding at level
j þ 1 but not at level j þ 2.
(Note that the BGOmethod with j¼ 1 is strongly blinding at level 3,
same as the BGO method with j ¼ 2.)
Proof of Theorem A1
The proof is based on the construction of “solutions” and to
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assignment of kits to kit types that are consistent with all the in-
formation known to the investigator. Speciﬁcally to show that the
BGO method is strongly blinding at level n, we show that for any
n þ 1 kits at the site, after unblinding the investigator to the ﬁrst
n  1 kits, there exist, regardless of the kit types of the ﬁrst n  1
kits, the following four solutions:
S1 A solution in which kit n is assigned to active,
S2 A solution in which kit n is assigned to placebo,
S3 A solution in which kits n and n þ 1 have the same kit type,
and
S4 A solution in which kits n and n þ 1 have opposite kit types.
When all four solutions exist, it is not possible for the investi-
gator to unblind kit n or to partially unblind kits n and n þ 1 even
after learning the kit types of the ﬁrst n  1 kits. We will use the
notation X1,…, Xn1 for the ﬁrst n  1 kits, and Xn and Xnþ1 for kit n
and kit n þ 1 respectively.
BGO method with j ¼ 1
After the initial shipment and every resupply shipment, the
site's inventory will consist of 2k þ 1 kits: k active kits, k placebo
kits and one random kit. Resupply shipments, each consisting of a
single kit, are sent after dosing each subject.
During the trial, information in the site's inventory available to
the investigator can be summarized in an inventory table, where
columns represent the “snapshots” of the inventory after each
supply (initial supply or a resupply). Unused kits from the previous
column remain in the same rows.
Consider the following hypothetical example (using BGO
method with k ¼ 2 and j ¼ 1): a site enrolled a total of 10 subjects
during the course of the study (thus a total of 15 kits have been sent
to the site) and kits #3, 6, 7, 2, 1, 5, 9, 4, 12, and 11 were given in this
order to dose the 10 subjects. The inventory table as described
above is shown in Table A1.Table A1
Inventory table, showing the kit numbers of kits in the inventory, for the hypothetical example. Kits that are new to the inventory are in bold.
Initial inventory Inventory after ith resupply Final inventory
i ¼ 1 i ¼ 2 i ¼ 3 i ¼ 4 i ¼ 5 i ¼ 6 i ¼ 7 i ¼ 8 i ¼ 9 i ¼ 10
1 1 1 1 1 10 10 10 10 10 10 10
2 2 2 2 9 9 9 12 12 14 14 14
3 6 7 8 8 8 8 8 8 8 8 8
4 4 4 4 4 4 4 4 13 13 13 13
5 5 5 5 5 5 11 11 11 11 15 15The only constraint on the inventory imposed by the BGO
method is that each column of Table A1must contain aminimum of
2 placebo and 2 active kits. There aremany solutions that assign kits
to kit types (active or placebo) that satisfy this constraint. To prove
Theorem A1 for j ¼ 1, we will need two classes of solutions, “trivial”
solutions and “change over” solutions.
A trivial solution consists of k ﬁxed active rows, k ﬁxed placebo
rows and one free row. All kits in a ﬁxed row are assigned to the
same kit type, either active or placebo. Kits in the free row can be
assigned to either kit type. For example a trivial solution for the
hypothetical example sets rows 1 and 2 to active, rows 3 and 4 to
placebo, and row 5 as a free row. That is, kits (1, 2, 9, 10, 12, 14) are
active kits, kits (4, 6, 7, 8, 13) are placebo kits, and kits (5, 11, 15) in
row 5 can be any of the 8 combinations of kit types, i.e., (a, a, a),
(a,a,p), …, (p,p,p), where a ¼ active and p ¼ placebo.A change over solution consists of 2k  1 ﬁxed rows and two
“change” rows: an “active” change row (which is a change row that
begins with an active kit) and a “placebo” change row (which is a
change row that begins with a placebo kit). A change row has a
single change point in the row. The row begins with one type of kit
and then changes to the other type. For example in the hypothetical
example, if kits 2 and 9 are set to active and kits 12 and 14 are set to
placebo in row 2, then row 2 is an active change row with the
change point in between kits 9 and 12. The key observation is that
the two change rows will contribute one active and one placebo kit
to the inventory before the ﬁrst change point and after the second
change point. Between the two change points, the two change rows
will either contribute two active kits or two placebo kits depending
on which change point occurs ﬁrst. If the change rows contribute
two active (placebo) kits between the two change points, then
setting k ﬁxed rows to placebo (active) and k 1 ﬁxed row to active
(placebo) will satisfy the constraints.
To prove that BGO with j ¼ 1 is strongly blinding at level 3, we
need to obtain solutions S1e4 for an arbitrary selection of 4 kits (X1,
X2, X3, X4) from the site, regardless of the kit types given for X1 and
X2.
Finding solutions S1 and S2 is equivalent to demonstrating that
it is possible to assign kits (X1, X2, X3) to any of the 8 combinations of
kit types regardless of the locations of the three kits (in the in-
ventory table). Only trivial solutions are needed to obtain solutions
S1 and S2. There are 3 cases:
1. The three kits are in distinct rows e each of the three rows can
be either a ﬁxed active row or a ﬁxed placebo row.
2. The three kits are in the same row emake this row the free row
to obtain all eight treatment combinations.
3. Two kits are in one row and the other kit is in another e make
the row with the two kits the free row.
To obtain solutions S3 and S4, there are 6 cases to consider:
1. The four kits are in the same row.2. The four kits are in distinct rows.
3. Three kits are in one row and the other kit is in another row.
4. Two kits are in one row and the other kits are in distinct rows.
5. X1 and X3 are in one row and X2 and X4 are in another row.
6. X1 and X2 are in one row and X3 and X4 are in another row.
It should be noted that unlike ﬁnding S1 and S2, ﬁnding solu-
tions S3 and S4 is not the same as demonstrating the possibility of
assigning kits (X1, X2, X3, X4) to any of the 16 combinations of kit
types regardless of the locations of the four kits. For example,
suppose kits (X1, X2, X3, X4) are four of the initial kits, then it is not
possible to assign all of them to active for the BGO method with
k ¼ 2.
Without going into details, we claim that trivial solutions can be
easily obtained except for case 6 where difﬁculty arises in
R. Yu, D.A. Coleman / Contemporary Clinical Trials Communications 1 (2015) 22e27 27establishing a trivial solution in which X1 and X2 are of opposite kit
types and kits X3 and X4 are of opposite kit types as there is only one
free row. Here a “change over” solution is needed.
To construct the change over solution for case 6, make the two
rows containing kits (X1, X2, X3, X4) two change rows and for each
change row, set the change point to any place between the two
selected kits in the row. Without loss of generality, assume that X2
arrives at the site after X1 and X4 arrives at the site after X3. If X1 is an
active (placebo) kit, make the row containing X3 and X4 a placebo
(active) change row. The selected kits in each of the change rows
will have opposite kit types (because they fall on opposite sides of
the change point) thus completing the proof of the assertion that
BGO method with j ¼ 1 is strongly blinding at level 3.
The BGO method with j ¼ 1 is not strongly blinding at level 4
because suppose that the ﬁrst 2 kits used at the site come from the
initial shipment, if the investigator learns that both are active kits
and the ﬁrst resupply is a placebo kit, then the investigator can
conclude with certainty that the second resupply is an active kit.
BGO method with j > 1
After the initial shipment and every resupply shipment, a site's
inventory will consist of 2k þ 1 kits: k active kits, k placebo kits and
one random kit. Each resupply shipment consists of j kits and is sent
after every j subjects. Similar to the previous case of j ¼ 1, infor-
mation in the site's inventory can be summarized in a table with
2kþ 1 rows. However because the size of the resupply shipments is
greater than 1, the inventory table is not unique (kits sent in the
same shipment can be permuted among themselves). In particular,
if N resupply shipments have been sent to the site, there are (j!)N
distinct inventory tables up to permutation of rows.
To prove that BGOwith j > 1 is strongly blinding at level jþ 1, we
need to obtain solutions S1e4 for an arbitrary selection of j þ 2 kits
(X1, …, Xjþ2) from the site, regardless of the kit types given for the
ﬁrst j kits (X1,…, Xj).
The following claim can be made: for any j kits, there exists an
inventory table such that each of the j kits is in a distinct row. This is
true because for each kit that arrives at the site, there are at a
minimum j possible rows to assign the kit to. Therefore an in-
ventory table in which the ﬁrst j kits (X1,…, Xj) are in distinct rows
can always be found.
There are two places for Xjþ1: in a new row or in a previously
occupied row. Therefore there are two cases to consider for the ﬁrst
j þ 1 kits (X1,…, Xjþ1):
1. All kits are in distinct rows.
2. Two kits are in one row and the other kits are in distinct rows.Trivial solutions can be easily obtained for S1 and S2.
Placement of Xjþ1 and Xjþ2 leads to the following 4 cases (after
possibly relabeling the kits):
1. All kits are in distinct rows.
2. Three kits are in one row and the other j  1 kits are in distinct
rows.
3. Two kits are in one row and other j kits are in distinct rows.
4. Kits X1 and Xjþ1 are in one row, kits X2 and Xjþ2 are in one row,
and the other j  2 kits are in distinct rows.
It can be seen that trivial solutions can also be obtained for S3
and S4.
The BGO method with j > 1 is not strongly blinding at level j þ 2
because if the ﬁrst j kits used at the site come from the initial
shipment, the investigator learns that they are active kits, and a kit
in the ﬁrst resupply is placebo, then the investigator can conclude
that the remaining kits in the ﬁrst resupply must be active kits. This
counterexample does not apply to the BGO method with j ¼ 1
because each resupply has only one kit. No kits remain in the ﬁrst
resupply after the placebo kit is unblinded.
It should be noted that in the proof of Theorem A1, it is assumed
that all kits of the appropriate kit type have a non-zero probability
of being selected when a subject needs a kit. If this is not the case,
e.g. kits in the earliest shipments are assigned ﬁrst (i.e., FIFO),
additional constraints on the solution space may be introduced and
Theorem A1 no longer holds.References
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